Alex Zukiwski

Global Chief Medical Officer

Dr. Zukiwski joined CASI in April 2017 as Global Chief Medical Officer.

Prior to joining CASI, Dr. Zukiwski was Chief Executive Officer and Chief Medical Officer of Arno Therapeutics, responsible for leading the clinical development and regulatory affairs teams to support the company's pipeline. Prior to Arno, Dr. Zukiwski served as Chief Medical Officer and Executive Vice President of Clinical Research at MedImmune. Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson’s (J&J,) . Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer.

Dr. Zukiwski has more than 20 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere^®, Xeloda^®, Procrit^®/Eprex^®, Velcade^®, Yondelis^®, and Doxil^®. 

Dr. Zukiwski holds a bachelor's degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.